Havrix

ApprovedBiologic

GSK

Havrix is one of 197 biologic programs targeting Japanese encephalitis. It is currently in Approved.

Indications

Total Trials

Active Trials

196

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

HepatitisActive, not recruiting

Acute Otitis MediaActive, not recruiting

MemoryActive, not recruiting

InfluenzaActive, not recruiting

CirrhosisActive, not recruiting

PapillomaActive, not recruiting

DiphtheriaActive, not recruiting

Japanese EncephalitisPhase 3

Active, not recruiting

HepatitisApproved

Active, not recruiting

Acute Otitis MediaPhase 3

Active, not recruiting

MemoryApproved

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

CirrhosisApproved

Active, not recruiting

PapillomaPhase 3

Active, not recruiting

DiphtheriaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Havrix

GSK

Approved

3 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Avigan

AAppili Therapeutics Inc.

Preclinical

6 5

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 6

COMIRNATY

Pfizer

Preclinical

1 7

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Fluvirin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Vaccine

NCT06824194

Q3 2027

Phase 3Active, not recruiting

Vaccination

NCT06824181

Clinical

Trials by Indication[1]

Immunogenicity12 trials

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

Completed·CCanadian Immunization Research Network·Phase 4·NCT02583412·120 enrolled

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Completed· GSK logo

GSK·Phase 3·NCT01978093·600 enrolled

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Completed· GSK logo

GSK·Phase 4·NCT01196026·162 enrolled

Show 9 more trials

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Completed· GSK logo

GSK·Phase 2·NCT00578175·1,851 enrolled

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Completed· GSK logo

GSK·Phase 2·NCT00861744·1,259 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Completed· GSK logo

GSK·Phase 3·NCT01681992·4,538 enrolled

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Completed· GSK logo

GSK·Phase 2·NCT02212457·1,063 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Completed· GSK logo

GSK·Phase 3·NCT02184572·1,742 enrolled

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Completed· Pfizer logo

Pfizer·Phase 3·NCT01830855·3,596 enrolled

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Completed· GSK logo

GSK·Phase 2·NCT00513409·163 enrolled

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Completed· GSK logo

GSK·Phase 3·NCT01702428·5,016 enrolled

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Terminated· GSK logo

GSK·Phase 4·NCT00544271·720 enrolled

Hepatitis9 trials

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Completed·CCrucell Holland BV·Phase 2·NCT01405677·308 enrolled

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Completed· GSK logo

GSK·Phase 4·NCT00291876·135 enrolled

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Completed· GSK logo

GSK·Phase 3·NCT00197015·1,474 enrolled

Show 6 more trials

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Withdrawn· GSK logo

GSK·Phase 3·NCT02082639

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Completed· GSK logo

GSK·Phase 4·NCT00289757·78 enrolled

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Completed· GSK logo

GSK·Phase 4·NCT00289731·596 enrolled

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

Completed· GSK logo

GSK·Phase 4·NCT00603252·213 enrolled

Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 4·NCT00534885·400 enrolled

Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel

Withdrawn· GSK logo

GSK·Phase 4·NCT03183492

Influenza3 trials

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Completed· GSK logo

GSK·Phase 3·NCT01218308·5,220 enrolled

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Completed· GSK logo

GSK·Phase 3·NCT01439360·12,046 enrolled

A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children

Completed· GSK logo

GSK·Phase 3·NCT01379937·520 enrolled

Memory2 trials

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Completed· GSK logo

GSK·Phase 4·NCT00684671·506 enrolled

Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult

Completed· GSK logo

GSK·Phase 4·NCT01000324·44 enrolled

Vaccine1 trial

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06824194·2,320 enrolled

12 more indications

Terminated·CClover Biopharmaceuticals AUS Pty·Phase 3·NCT05012787·1 enrolled

Diphtheria1 trial

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Completed· GSK logo

GSK·Phase 3·NCT00197236·468 enrolled

Japanese encephalitis1 trial

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Completed·VValneva Austria GmbH·Phase 3·NCT00596271·192 enrolled

Papilloma1 trial

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00316706·1,245 enrolled

Cirrhosis1 trial

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis

Recruiting·MMahidol University·Phase 4·NCT06277882·50 enrolled

Herpes Simplex1 trial

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Completed· GSK logo

GSK·Phase 3·NCT00224484·5,960 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06824181·580 enrolled

Children1 trial

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00624819·524 enrolled

Acute otitis media1 trial

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00466947·23,802 enrolled

Adult1 trial

Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult

Completed· GSK logo

GSK·Phase 4·NCT01037114·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 39 trial records for Havrix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Havrix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Havrix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GSK

Havrix

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Immunogenicity12 trials

Hepatitis9 trials

Influenza3 trials

Memory2 trials

Vaccine1 trial

Plasmodium Falciparum1 trial

Bone Marrow Transplant1 trial

Immune-mediated Diseases1 trial

Diphtheria1 trial

Japanese encephalitis1 trial

Papilloma1 trial

Cirrhosis1 trial

Herpes Simplex1 trial

Vaccination1 trial

Children1 trial

Acute otitis media1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News